Skip to content
Beovu(brolucizumab)
Beovu (brolucizumab) is an antibody pharmaceutical. Brolucizumab was first approved as Beovu on 2019-10-07. It is used to treat wet macular degeneration in the USA. It has been approved in Europe to treat wet macular degeneration. The pharmaceutical is active against vascular endothelial growth factor A. In addition, it is known to target Vascular endothelial growth factor A.
Download report
Favorite
Novartis Pharmaceuticals
FDA Novel Drug Approvals 2019
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
eye diseasesD005128
Trade Name
FDA
EMA
Beovu
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Brolucizumab
Tradename
Proper name
Company
Number
Date
Products
Beovubrolucizumab-dbllNovartis Pharmaceuticals CorporationN-761125 RX2019-10-07
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
beovuBiologic Licensing Application2021-02-25
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
wet macular degenerationEFO_0004683D057135—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01L: Ocular vascular disorder agents
— S01LA: Antineovascularisation agents
— S01LA06: Brolucizumab
HCPCS
Code
Description
J0179
Injection, brolucizumab-dbll, 1 mg
Clinical
Clinical Trials
47 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Macular degenerationD008268EFO_0001365H35.30141251233
Wet macular degenerationD057135EFO_0004683——12—3
Retinal diseasesD012164HP_0000479H35.9——11—2
Retinal degenerationD012162HP_0001105——11—2
Eye diseasesD005128EFO_0003966H44——11—2
Retinal dystrophiesD058499Orphanet_71862———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Macular edemaD008269——5—16
Retinal vein occlusionD012170EFO_1001157H34.81——2——2
Choroidal neovascularizationD020256——2——2
EdemaD004487R60.9——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InflammationD007249————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBROLUCIZUMAB
INNbrolucizumab
Description
Brolucizumab sold under trade name Beovu among others, is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID1531589-13-5
RxCUI2204915
ChEMBL IDCHEMBL3707357
ChEBI ID—
PubChem CID—
DrugBankDB14864
UNII IDXSZ53G39H5 (ChemIDplus, GSRS)
Target
Agency Approved
VEGFA
VEGFA
Organism
Homo sapiens
Gene name
VEGFA
Gene synonyms
VEGF
NCBI Gene ID
7422
Protein name
vascular endothelial growth factor A
Protein synonyms
vascular endothelial growth factor A121, vascular endothelial growth factor A165, Vascular permeability factor, VPF
Uniprot ID
P15692
Mouse ortholog
Vegfa (22339)
vascular endothelial growth factor A (Q00731)
Alternate
VEGFA
VEGFA
Organism
Homo sapiens
Gene name
VEGFA
Gene synonyms
NCBI Gene ID
—
Protein name
Vascular endothelial growth factor A
Protein synonyms
Vascular permeability factor
Uniprot ID
H0YBI8
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
Beovu - Novartis
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 652 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,035 adverse events reported
View more details